|
|
| Industrie Pharmaceutique > Etude de marché sectorielle |
| Financial Markets Research: Spectrum Pharmaceuticals' Oral Satraplatin - Oral therapy to take share in second-line hormone-refractory prostate cancer market |
|
|
|
|
€ 3 040,00 |
Editeur
: |
Datamonitor |
Langue
: |
Anglais |
Date de publication : |
Septembre 2006 |
Taille du document : |
12 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
Documents Publics |
1,200,000
documents |
Téléchargement illimités |
|
|
|
Etudes Privées |
50,000 rapports et études |
Paiement à la piéce |
|
|
|
|
| |
|
1.Télécharger nos rapports publics
Accés complet à plus de 1,2 Million de documents publics : études de marché, statistiques sectorielles, fiches pays, monographie d'entreprises, veille concurentielle, rapports annuels...
|
| Nos documents publics sur le même théme (1) |
|
|
|
| 74 pages | Janvier 2002 | Anglais
|
|
|
| Main
focus: |
cancer,breast cancer,prostate cancer,lung cancer,...,...
|
| Research
focus: |
market definition,market outlook |
| Geographic
focus: |
canada,france,australia |
| |
|
|
|
|
| Autres recherches sur le même thème |
|
|
|
| |
| |
|
| |
|
2.
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
Pharmaceutical Pricing Strategies 2000: Entering the new millennium
240 pages | Juin 2000 |
The favorable climate of the pharmaceutical sector has changed radically over the past ten years.
Where once a company's freedom over pricing decisions was almost limitless, external pressure |
955,00 €
|
| |
| |
The Pharmaceutical industry in the 21st Century
150 pages | Octobre 1998 |
Does the 21st century herald the beginning of a genomics revolution? Which disease areas will provide the greatest growth potential and why? Which technologies have the greatest potential to max |
795,00 €
|
| |
| |
Chinese Markets for OTC Drugs
220 pages | Février 2002 |
China's demand for OTC drugs has grown at a fast pace in the past decade.
In the next five years, both production and demand will continue to grow.
This new study examines China's economic trend |
3 500,00 €
|
| |
| |
The Drug Discovery Outlook: Drivers of innovation in the 21st Century
189 pages | Octobre 2000 |
The Drug Discovery Outlook: Drivers of innovation in the 21st Century introduces and analyzes the five key enabling technologies and bioinformatics, which are currently driving pharmaceutical dru |
955,00 €
|
| |
| |
Patient Power Outlook 2001
152 pages | Juillet 2001 |
The increase in patient power witnessed over the last decade has been driven by developments in healthcare systems, patient advocacy activity, the increasing influence of the media in healthcare issue |
955,00 €
|
| |
| |
The Pharmaceutical Profitability Outlook
150 pages | Février 1999 |
Is pharmaceutical profitability sustainable into the 21st century? “As the pharmaceutical industry finds itself at a crossroads, the strategic directions companies take will be pivotal in determini |
795,00 €
|
| |
| |
Global Pharmaceutical: a market, company and disease analysis
150 pages | Octobre 1998 |
What will drive pharmaceutical market growth into the 21st Century? What are the key challenges facing pharmaceutical manufacturers? Who are the market leaders in each sector? What strategies ar |
795,00 €
|
| |
| |
The Drug Delivery Outlook 2001
176 pages | Juillet 2001 |
In an environment where there is constant pressure to launch new products onto the market, the cost of investment in drug delivery compares very favourably with new drug discovery.
Subseque |
955,00 €
|
| |
| |
Lifestyle Drugs Outlook to 2005
130 pages | Février 1999 |
Definition of lifestyle drugs : The disease, product and social characteristics that make a drug lifestyle drug.
Epidemiology : The patient potential for lifestyle drugs such as sexual dysfuncti |
795,00 €
|
| |
| |
The Diagnostics Outlook to 2005
130 pages | Février 1999 |
Diagnostic market : The current in vitro diagnostic (IVD) market is discussed, identifying how the market can be segmented according to country, end user, clinical speciality and disease area.
795,00 €
|
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Financial Markets Research: Spectrum Pharmaceuticals' Oral Satraplatin - Oral therapy to take share in second-line hormone-refractory prostate cancer market |
|
|
Introduction
There are no FDA-approved second-line chemotherapy options for hormone refractory prostate cancer, indicating a great unmet need, with a large potential market for an agent such as Spectrum's satraplatin, which could offer key advantages due to its oral administration profile.
Scope
Analysis of the regulatory and commercial potential for SPPI's oral satraplatin, the first agent to demonstrate activity in second-line HRPC patients
Interviews with 5 prostate cancer specialists regarding trends in the treatment of this disease and the potential role for a second-line HRPC option
Highlights
Given its novel oral administration profile and promising efficacy data from a small European trial, if approved, we believe Spectrum Pharmaceuticals' (SPPI) and GPC Biotech's (GPCB) satraplatin could become a widely popular treatment option for second-line hormone-refractory prostate cancer (HRPC) patients.
Pending results from the recently enrolled Phase III SPARC trial, we anticipate that satraplatin, a third generation platinum agent, could be approved for HRPC as early as mid-2007 and forecast significant revenues for the companies.
Reasons to Purchase
Predict the regulatory and commercial potential for SPPI's oral satraplatin through in-depth analysis based on interviews with leading experts
Anticipate likely changes in the future market dynamics for hormone-refractory prostate cancer therapies upon possible launch of oral satraplatin
|
|
Introduction
There are no FDA-approved second-line chemotherapy options for hormone refractory prostate cancer, indicating a great unmet need, with a large potential market for an agent such as Spectrum's satraplatin, which could offer key advantages due to its oral administration profile.
Scope
Analysis of the regulatory and commercial potential for SPPI's oral satraplatin, the first agent to demonstrate activity in second-line HRPC patients
Interviews with 5 prostate cancer specialists regarding trends in the treatment of this disease and the potential role for a second-line HRPC option
Highlights
Given its novel oral administration profile and promising efficacy data from a small European trial, if approved, we believe Spectrum Pharmaceuticals' (SPPI) and GPC Biotech's (GPCB) satraplatin could become a widely popular treatment option for second-line hormone-refractory prostate cancer (HRPC) patients.
Pending results from the recently enrolled Phase III SPARC trial, we anticipate that satraplatin, a third generation platinum agent, could be approved for HRPC as early as mid-2007 and forecast significant revenues for the companies.
Reasons to Purchase
Predict the regulatory and commercial potential for SPPI's oral satraplatin through in-depth analysis based on interviews with leading experts
Anticipate likely changes in the future market dynamics for hormone-refractory prostate cancer therapies upon possible launch of oral satraplatin
|
|
|
PPLSEN
|
|
|
|
|
